2002, Drug Development and Patient Experience

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2002

Drug Development

Patient Experience

AngelEye Health Announces Series B Funding to Support Company’s Rapid Growth

Healthcare IT Today

NOVEMBER 14, 2022

Founded in 2002, MGP has invested in more than 50 companies in these sectors. Technology investments focus on business and healthcare technology, targeting those ideas with quantifiable development risk and a rapid path to market. Within Life Sciences, the firm focuses on MedTech, Diagnostics, and Opportunistic Drug Development.

Life Science

Life Science HIPAA Drug Development healthcare technology

Virtual Care – negotiating barriers to adoption offers glimpses of an exciting future

Lloyd Price

DECEMBER 11, 2023

It may be a good while before we reach pre-cognitive techniques to ward off disease and accidents, but virtual reality is forging radical recalibrations of everything from drug discovery to bedside care in both the home and the hospital setting. The patient experience needs to be positive to ensure engagement and adherence.

Pharmaceuticals

Pharmaceuticals Digital Health Drug Development Life Science

Connected Health Pulse

AngelEye Health Announces Series B Funding to Support Company’s Rapid Growth

Virtual Care – negotiating barriers to adoption offers glimpses of an exciting future

Stay Connected